scholarly journals Quality of Life Assessment in Patients with Multiple Sclerosis Receiving Interferon Beta-1a: A Comparative Longitudinal Study of Avonex and Its Biosimilar CinnoVex

2012 ◽  
Vol 2012 ◽  
pp. 1-6 ◽  
Author(s):  
R. Abolfazli ◽  
A. Hosseini ◽  
Kh. Gholami ◽  
M. R. Javadi ◽  
H. Torkamandi ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Multiple Sclerosis ◽  
Longitudinal Study ◽  
Physical Health ◽  
Interferon Beta ◽  
Cost Effective ◽  
Life Assessment ◽  
Significant Difference ◽  
Composite Scores

Background. Multiple sclerosis (MS) is an autoimmune inflammatory disease of central nervous system (CNS). MS affects quality of Life (QOL) due to physical disability and other associated problems. Disease-modifying agents like interferon beta (IFNB) have been widely utilized in this patient population; however, their frequency, route of administration, side effects, high cost, and also the question of whether they are truly beneficial for longer-term outcomes and QOL need to be further investigated. Objectives. To assess QOL in patients with multiple sclerosis receiving interferon beta-1a (Avonex or CinnoVex) and in order to compare QOL in groups receiving Avonex and CinnoVex, respectively, also, to evaluate whether the more cost-effective biosimilar form of IFNB (CinnoVex) has the same effect on QOL and can be substituted for Avonex. Methods. We conducted a 30-month, nonrandomized longitudinal study and recruited a total of 92 patients diagnosed with relapsing-remitting MS. The patients were distributed in Avonex and CinnoVex groups with 46 patients in each group. Quality of life was assessed by means of MSQOL-54 questionnaire, four times a year, at baseline and at months 4, 8, and 12 of the study. Results. Mean age ± SD was 30.5 ± 8.9 and 32.3 ± 9.0 years in Avonex and CinnoVex groups, respectively, and P value of gender was different (P value : 0.036). The physical health composite scores were 61.8 and 59.8 (P values 0.677 and 0.884) for Avonex and CinnoVex groups, in that order. The results of the study revealed no significant difference between the two groups with regard to physical health, health perception, energy, and role limitations due to physical problems, pain, sexual and social function, and physical health distress scores. Further, interferon therapy did not significantly impact patients’ QOL after a year of treatment with either Avonex or CinnoVex. Conclusions. According to the present study, treatment with IFNB (Avonex or CinnoVex) did not affect QOL during a year of therapy. Further studies with longer follow-up periods are required to assess the value of interferons on long-term outcomes and patient’s QOL.

scholarly journals Quality of life, depression and fatigue in mildly disabled patients with relapsing–remitting multiple sclerosis receiving subcutaneous interferon beta-1a: 3-year results from the COGIMUS (COGnitive Impairment in MUltiple Sclerosis) study

2011 ◽  
Vol 17 (8) ◽  
pp. 991-1001 ◽  
Author(s):  
F Patti ◽  
MP Amato ◽  
M Trojano ◽  
S Bastianello ◽  
MR Tola ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Multiple Sclerosis ◽  
Cognitive Impairment ◽  
Interferon Beta ◽  
Rating Scale ◽  
Cognitive Status ◽  
Treatment Dose ◽  
Relapsing Remitting ◽  
Composite Scores

Background: The precise relationships among quality of life, depression, fatigue and cognitive impairment in multiple sclerosis (MS) are complex and poorly understood. Objective: To assess the effects of subcutaneous interferon beta-1a on quality of life, depression and fatigue over 3 years in the COGIMUS study, and to examine the relationship between these outcomes and baseline cognitive status. Methods: COGIMUS was an observational 3-year trial assessing cognitive function in 459 patients with relapsing–remitting MS treated with subcutaneous interferon beta-1a. Results: In total, 331 patients completed the study (168 received interferon beta-1a, 44 µg subcutaneously three times weekly, and 163 received interferon beta-1a, 22 µg subcutaneously three times weekly). Mean MS Quality of Life-54 (MSQoL-54) composite scores did not change over time. There were no significant differences between groups in MSQoL-54 composite scores when patients were grouped by treatment dose and baseline cognitive status. Mean (standard deviation) Hamilton Depression Rating Scale score decreased from 6.8 (4.9) at baseline to 5.8 (5.9) at year 3. Mean total Fatigue Impact Scale scores were low (<30) at all time points. Conclusion: Quality of life, depression and fatigue remained largely stable over 3 years; no effects of treatment dose or baseline cognitive status were found.

A longitudinal study of quality of life and side effects in patients with multiple sclerosis treated with interferon beta-1a

2003 ◽  
Vol 216 (1) ◽  
pp. 113-118 ◽  
Author(s):  
Robert Zivadinov ◽  
Marino Zorzon ◽  
Maria Antonietta Tommasi ◽  
Davide Nasuelli ◽  
Monica Bernardi ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Multiple Sclerosis ◽  
Longitudinal Study ◽  
Side Effects ◽  
Interferon Beta

Long-Term Effectiveness of Fingolimod for Multiple Sclerosis in a Real-World Clinical Setting

2021 ◽  
pp. 1-6
Author(s):  
Cihat Uzunköprü ◽  
Yesim Beckmann ◽  
Sabiha Türe
Keyword(s):  
Quality Of Life ◽  
Multiple Sclerosis ◽  
Real Life ◽  
Life Assessment ◽  
Health Related Quality ◽  
Serious Adverse Events ◽  
Related Quality ◽  
Health Related

<b><i>Introduction:</i></b> The primary aim of the present study was to evaluate the long-term efficacy of fingolimod in patients with multiple sclerosis (MS); secondary aims were to describe the safety of fingolimod with the evaluation of treatment satisfaction and impact on the quality of life in real life. <b><i>Methods:</i></b> We collected clinical, demographical, neuroradiological, and treatment data, including pre- and posttreatment status health-related quality of life from 286 MS patients consecutively treated with fingolimod. Clinical assessment was based on the Expanded Disability Status Scale (EDSS), and quality of life assessment was performed with MS-related quality of life inventory (MSQOLI). The data were recorded at baseline and every 6 months for 2 years. <b><i>Results:</i></b> One hundred and fourteen males and 172 females were enrolled. The annualized relapse rate and EDSS showed a statistically significant reduction during the observation period (<i>p</i> &#x3c; 0.001). The patients also demonstrated substantial improvements in magnetic resonance imaging (MRI) outcomes (<i>p</i> &#x3c; 0.001). Health-related quality of life scores improved significantly between baseline and 24-month visit (<i>p</i> &#x3c; 0.001). No serious adverse events occurred. <b><i>Conclusion:</i></b> In our cohort, fingolimod treatment was associated with reduced relapse, MRI activity, and improved EDSS and MSQOLI scores. Additionally, fingolimod has been able to maintain its effectiveness over a considerable long period of treatment.

Multimorbidity and  health-related quality of life among people 55 years and up: results of a longitudinal study in New Zealand

2020 ◽  
Author(s):  
Nayyereh Aminisani ◽  
Chris Stephens ◽  
Fiona Alpass ◽  
Seyed Morteza Shamshirgaran
Keyword(s):  
Quality Of Life ◽  
Longitudinal Study ◽  
New Zealand ◽  
Inverse Association ◽  
Health Related Quality ◽  
Significant Difference ◽  
Related Quality ◽  
Health Related ◽  
Over Time

Abstract Background: This study aimed to examine the association of Health-Related Quality of Life (HRQOL) and multimorbidity (MM) and its correlates over time in New Zealand. Methods: People aged 55 years and over were invited to participate in a nationally representative population-based longitudinal study in 2006 and followed up biennially until 2016. Generalized Estimating Equations (GEE) with an exchangeable correlation matrix and robust standard errors adjusted for both time-constant and time-varying factors using baseline and five subsequent waves of data were used, to compare a range of factors related to changes in MM and HRQOL. Results: Of 2632 participants at baseline, 957 of the participants were classified as “MM participants”; 570 had two, and the rest had three chronic conditions. The results of the GEE regression models demonstrated that SF12-PCS decreased over time, and there was a significant difference in SF12-PCS between MM and Non-MM participants. Having MM was negatively associated with HRQOL-PCS [-3.00 (95 %CI -3.60, -2.49); p <0.001)]. Although the results showed an increase in SF12-MCS over time, the score of the mental dimension of HRQOL was lower among MM participants compared to Non-MM participants [-2.60, 95 %CI -3.09, -2.11]. Conclusions: According to this longitudinal study, there is an inverse association between MM and one of the most important health outcomes; HRQOL, in older adults.

scholarly journals Is Telephysiotherapy an Option for Improved Quality of Life in Patients with Osteoarthritis of the Knee?

2014 ◽  
Vol 2014 ◽  
pp. 1-9 ◽  
Author(s):  
Adesola C. Odole ◽  
Oluwatobi D. Ojo
Keyword(s):  
Quality Of Life ◽  
Physical Health ◽  
Osteoarthritis Of The Knee ◽  
Group Comparison ◽  
Treatment Groups ◽  
Knee Oa ◽  
Significant Difference ◽  
Environment Domain ◽  
Telephone Monitoring

This study investigated effect of a 6-week telephysiotherapy programme on quality of life (QoL) of patients with knee osteoarthritis (OA). Fifty patients with knee OA were randomly and equally assigned into two treatment groups: clinic group (CG) and telephysiotherapy group (TG). The CG received physiotherapist-administered osteoarthritis-specific exercises in the clinic thrice weekly for 6 weeks while the TG received structured telephone monitoring with self-administered osteoarthritis-specific exercises for the same duration at home. Participants’ QoL was assessed using WHOQoL-Bref at baseline, second, fourth, and sixth week of intervention. Data were analyzed using ANOVA and independent Student’st-test. Within-group comparison showed significant improvements in physical health domain (P=0.00*for TG and CG) and psychological domain (P=0.02*for TG;P=0.00*for CG) of WHOQoL following six-week intervention. However, there were no significant differences (P>0.05) in TG and CG’s social relationship and environment domains. Between-group comparison showed no significant differences (P>0.05) between CG and TG’s physical health, psychological, and social relationships domains of WHOQoL following 6-week intervention. However, there was significant difference in the environment domain (P<0.05). Telephysiotherapy using telephone medium improved QoL in patients with knee OA comparable to clinic based treatment.

Sign in / Sign up

Export Citation Format

Share Document